Last $4.03 USD
Change Today +0.04 / 1.00%
Volume 335.4K
NBS On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 03/4/15 All times are local (Market data is delayed by at least 15 minutes).

neostem inc (NBS) Snapshot

Open
$4.00
Previous Close
$3.99
Day High
$4.06
Day Low
$3.87
52 Week High
03/13/14 - $7.98
52 Week Low
12/12/14 - $3.08
Market Cap
155.0M
Average Volume 10 Days
231.9K
EPS TTM
$-1.84
Shares Outstanding
38.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NEOSTEM INC (NBS)

Related News

No related news articles were found.

neostem inc (NBS) Related Businessweek News

No Related Businessweek News Found

neostem inc (NBS) Details

NeoStem, Inc., a biotechnology company, develops cell based therapeutics. It is developing a Phase III targeted cancer immunotherapy product to enhance the destruction of cancer initiating cells; a Phase II ischemic repair product candidate to treat damaged heart muscle following a heart attack; a Phase II immune modulation product candidate to treat type 1 diabetes and steroid resistant asthma; and an investigational technology to repair or replace damaged or aged tissue, cells, and organs. The company, through its subsidiary, Progenitor Cell Therapy, offers contract development and manufacturing services. It also collects, processes, and stores umbilical cord blood units and adult stem cells. NeoStem, Inc. was founded in 1980 and is headquartered in New York, New York.

neostem inc (NBS) Top Compensated Officers

Executive Chairman
Total Annual Compensation: $945.0K
Chief Scientific Officer, President of Progen...
Total Annual Compensation: $494.2K
Chief Medical Officer
Total Annual Compensation: $331.5K
Vice President of Strategic Transactions
Total Annual Compensation: $319.6K
Compensation as of Fiscal Year 2013.

neostem inc (NBS) Key Developments

NeoStem, Inc. Announces Unaudited Earnings Results for the Year Ended December 31, 2014

NeoStem, Inc. announced unaudited earnings results for the year ended December 31, 2014. For the year, the company reported total revenue of $17.9 million compared to $14.7 million in 2013, an increase of 22%. Net loss for 2014 was $55.5 million compared with a $39.5 million loss for 2013. Net loss for 2014 excluding non-cash charges was $45.2 million, compared with $28.7 million for 2013.

Neostem, Inc. Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015

Neostem, Inc. Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015. Venue: The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St, 40th Floor (D Elevator Bank), New York, NY10007, United States. Presentation Date & Speakers: Feb-23-2015, Robert O. Dillman, Vice President of Oncology.

Neostem, Inc. Appoints Peter G. Traber as Director

Neostem, Inc. announced the addition of Peter G. Traber to its Board of Directors. Dr. Traber has experience in medicine, science and the pharmaceutical industry. He is currently President, Chief Executive Officer, and Chief Medical Officer of Galectin Therapeutics. Notably, he is president emeritus of Baylor College of Medicine, where he was Chief Executive Officer from 2003 to 2008. Dr. Traber also has extensive big pharma leadership experience serving from 2000 to 2003 as Senior Vice President of clinical development and medical affairs and Chief Medical Officer of GlaxoSmithKline. He has also served as CEO of the University of Pennsylvania Health System, Chair of the Department of Internal Medicine, and Chief of Gastroenterology for the University of Pennsylvania School of Medicine.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NBS:US $4.03 USD +0.04

NBS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Athersys Inc $2.97 USD +0.06
Cesca Therapeutics Inc $0.90 USD +0.0009
Cytori Therapeutics Inc $1.14 USD -0.06
StemCells Inc $1.24 USD -0.14
Vericel Corp $3.65 USD +0.10
View Industry Companies
 

Industry Analysis

NBS

Industry Average

Valuation NBS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.0x
Price/Book 2.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEOSTEM INC, please visit www.neostem.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.